The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ambap19767-45-4     sodium 2-sulfanylethanesulfonate

This record was replaced with 598.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of coenzyme M


High impact information on coenzyme M


Chemical compound and disease context of coenzyme M


Biological context of coenzyme M


Anatomical context of coenzyme M


Associations of coenzyme M with other chemical compounds


Analytical, diagnostic and therapeutic context of coenzyme M


  1. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Mulder, P.O., Sleijfer, D.T., Willemse, P.H., de Vries, E.G., Uges, D.R., Mulder, N.H. Cancer Res. (1989) [Pubmed]
  2. Protective role of thiols in cyclophosphamide-induced urotoxicity and depression of hepatic drug metabolism. Berrigan, M.J., Marinello, A.J., Pavelic, Z., Williams, C.J., Struck, R.F., Gurtoo, H.L. Cancer Res. (1982) [Pubmed]
  3. Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis. Weller, P.H., Ingram, D., Preece, M.A., Matthew, D.J. Thorax (1980) [Pubmed]
  4. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Falkson, G., Van Dyk, J.J., Stapelberg, R., Falkson, H.C. Cancer Chemother. Pharmacol. (1982) [Pubmed]
  5. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna). Habs, M.R., Schmähl, D. Cancer (1983) [Pubmed]
  6. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Bryant, B.M., Jarman, M., Ford, H.T., Smith, I.E. Lancet (1980) [Pubmed]
  7. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector. Verschraagen, M., Zwiers, T.H., Torun, E., Donker, M.G., Reinhoud, N.J., Van der Vijgh, W.J. Journal of pharmaceutical sciences. (2003) [Pubmed]
  8. Oral bioavailability of mesna tablets. Stofer-Vogel, B., Cerny, T., Borner, M., Lauterburg, B.H. Cancer Chemother. Pharmacol. (1993) [Pubmed]
  9. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis. Ehrlich, R.M., Freedman, A., Goldsobel, A.B., Stiehm, E.R. J. Urol. (1984) [Pubmed]
  10. Single ototopical application of mesna has no ototoxic effects on guinea pig cochlear hair cells: a morphological study. Van Spaendonck, M.P., Timmermans, J.P., Claes, J., Scheuermann, D.W., Wuyts, F.L., Van de Heyning, P.H. Acta Otolaryngol. (1999) [Pubmed]
  11. Hemorrhagic cystitis--a manifestation of graft versus host disease? Ost, L., Lönnqvist, B., Eriksson, L., Ljungman, P., Ringdén, O. Bone Marrow Transplant. (1987) [Pubmed]
  12. Mistabron effects on platelets and blood coagulation. Henry, R.L., Washnock, M.A., Taylor, G.W. J. Int. Med. Res. (1984) [Pubmed]
  13. Interaction of Mesna (2-mercaptoethane sulfonate) with the mutagenicity of cyclophosphamide in vitro and in vivo. Lähdetie, J., Räty, R., Sorsa, M. Mutat. Res. (1990) [Pubmed]
  14. Arginine 2-mercaptoethane sulfonate and sodium 2-mercaptoethane sulfonate: a comparative study of their effects upon tumour cells. Magnolfi Zipoli, G., D'Ancona, S., Berti, T. Drugs under experimental and clinical research. (1988) [Pubmed]
  15. U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Cohen, M.H., Dagher, R., Griebel, D.J., Ibrahim, A., Martin, A., Scher, N.S., Sokol, G.H., Williams, G.A., Pazdur, R. Oncologist (2002) [Pubmed]
  16. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Kurowski, V., Wagner, T. Cancer Chemother. Pharmacol. (1997) [Pubmed]
  17. Chemically assisted capsulectomy in the rabbit model: a new approach. Ajmal, N., Riordan, C.L., Cardwell, N., Nanney, L.B., Shack, R.B. Plast. Reconstr. Surg. (2003) [Pubmed]
  18. Mistabron in the intensive care unit. Van De Walle, J., Lauwers, P., Adriaensen, H. Acta anaesthesiologica Belgica. (1976) [Pubmed]
WikiGenes - Universities